Litigation Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)
✉ Email this page to a colleague
Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)
| Docket | ⤷ Sign Up | Date Filed | 2023-11-07 |
| Court | District Court, N.D. West Virginia | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Thomas Shawn Kleeh |
| Jury Demand | None | Referred To | |
| Patents | 7,094,781 | ||
| Link to Docket | External link to docket | ||
Details for Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2023)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2024-03-22 | 18 | Answer to Complaint | United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively… be a patent infringement action alleging infringement of United States Patent Nos. 7,094,781 (“the’781…: INVALIDITY OF U.S. PATENT NO. 7,094,781 The claims of the ’781 patent are invalid for failure…AFFIRMATIVE DEFENSE: NONINFRINGEMENT OF U.S. PATENT NO. 7,094,781 Mylan has not infringed, induced…’781 patent”) and 10,946,015 (“the ’015 patent”) pursuant to the patent laws of the United States, 35 | External link to document |
| 2024-04-12 | 20 | Amended Complaint | United States Patent Nos. 7,094,781 (“the ’781 patent”) and 10,946,015 (“the ’015 patent”) (collectively…781 patent, titled “Sulfamides and Their Use as Endothelin Receptor Antagonists.” The ’781 patent duly… the ’781 patent is attached as Exhibit A. 17. Actelion Ltd owns the ’015 patent, titled “…Pyrimidine-Sulfamide.” The ’015 patent duly and legally issued on March 16, 2021. A copy of the ’015 patent is attached …contentions regarding patent validity, Mylan’s Notice Letter with respect to the ’781 patent does not identify | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
